BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26681199)

  • 1. Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro.
    Lee E; Jin D; Lee BB; Kim Y; Han J; Shim YM; Kim DH
    BMC Cancer; 2015 Dec; 15():982. PubMed ID: 26681199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer.
    Ko E; Kim Y; Park SE; Cho EY; Han J; Shim YM; Park J; Kim DH
    Lung Cancer; 2012 Aug; 77(2):401-6. PubMed ID: 22534667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
    Brambilla E; Moro D; Gazzeri S; Brambilla C
    J Pathol; 1999 Aug; 188(4):351-60. PubMed ID: 10440744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
    Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
    Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer.
    Keum JS; Kong G; Yang SC; Shin DH; Park SS; Lee JH; Lee JD
    Br J Cancer; 1999 Sep; 81(1):127-32. PubMed ID: 10487623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YB-1 promotes transcription of cyclin D1 in human non-small-cell lung cancers.
    Harada M; Kotake Y; Ohhata T; Kitagawa K; Niida H; Matsuura S; Funai K; Sugimura H; Suda T; Kitagawa M
    Genes Cells; 2014 Jun; 19(6):504-16. PubMed ID: 24774443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer.
    Wang Y; Dong QZ; Fu L; Stoecker M; Wang E; Wang EH
    Mol Carcinog; 2013 Nov; 52(11):890-9. PubMed ID: 22753141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of cyclin D1 and vascular endothelial growth factor(VEGF) in non-small cell lung carcinoma and their association with the prognosis].
    Liang RY; Liao ZS; Jiang SP; Zhang W; Li JG; Zheng DH
    Ai Zheng; 2003 Jan; 22(1):86-90. PubMed ID: 12561444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The cyclin A, B1, D1 and E expression in advanced non-small cell lung cancer--stages IIIB-IV (preliminary report)].
    Kosacka M; Piesiak P; Porebska I; Korzeniewska A; Jankowska R
    Pol Merkur Lekarski; 2011 Apr; 30(178):253-8. PubMed ID: 21595169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homeobox Transcription Factor NKX2-1 Promotes
    Harada M; Sakai S; Ohhata T; Kitagawa K; Mikamo M; Nishimoto K; Uchida C; Niida H; Kotake Y; Sugimura H; Suda T; Kitagawa M
    Mol Cancer Res; 2017 Oct; 15(10):1388-1397. PubMed ID: 28634225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of β-Catenin and Cyclin D1 is Associated with Poor Overall Survival in Patients with Stage IA-IIA Squamous Cell Lung Cancer Irrespective of Adjuvant Chemotherapy.
    Kim Y; Jin D; Lee BB; Cho EY; Han J; Shim YM; Kim HK; Kim DH
    J Thorac Oncol; 2016 Dec; 11(12):2193-2201. PubMed ID: 27498289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients.
    Sterlacci W; Fiegl M; Hilbe W; Jamnig H; Oberaigner W; Schmid T; Augustin F; Auberger J; Obermann EC; Tzankov A
    J Thorac Oncol; 2010 Sep; 5(9):1325-36. PubMed ID: 20631637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells.
    Liu Y; Wang L; Lin XY; Wang J; Yu JH; Miao Y; Wang EH
    Tumour Biol; 2013 Jun; 34(3):1641-50. PubMed ID: 23423709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer.
    Saitoh G; Sugio K; Ishida T; Sugimachi K
    Oncol Rep; 2001; 8(4):737-43. PubMed ID: 11410775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4.
    Li D; Luo Y; Gao Y; Yang Y; Wang Y; Xu Y; Tan S; Zhang Y; Duan J; Yang Y
    Int J Mol Med; 2016 Sep; 38(3):927-36. PubMed ID: 27431575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer.
    Khoury T; Alrawi S; Ramnath N; Li Q; Grimm M; Black J; Tan D
    Clin Lung Cancer; 2009 Jan; 10(1):58-66. PubMed ID: 19289374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3 and cyclin D1 expression in non-small cell lung cancer.
    Kosacka M; Piesiak P; Kowal A; Gołecki M; Jankowska R
    J Exp Clin Cancer Res; 2011 Oct; 30(1):101. PubMed ID: 22024187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
    Ma T; Galimberti F; Erkmen CP; Memoli V; Chinyengetere F; Sempere L; Beumer JH; Anyang BN; Nugent W; Johnstone D; Tsongalis GJ; Kurie JM; Li H; Direnzo J; Guo Y; Freemantle SJ; Dragnev KH; Dmitrovsky E
    Mol Cancer Ther; 2013 Aug; 12(8):1545-55. PubMed ID: 23686769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.